Source: Indian Pharma Post

AVEO: AVEO Oncology announces acceptance of late-breaking oral presentation of TiNivo-2 results at ESMO 2024

Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab

Read full article »
AVEO's Competitors | AVEO's News | AVEO's Financials
Stay up-to-date with the latest news on AVEO
Est. Annual Revenue
$25-100M
Est. Employees
100-250
Michael P. Bailey's photo - President & CEO of AVEO

President & CEO

Michael P. Bailey

CEO Approval Rating

83/100

Read more
Stay up-to-date with the latest news on AVEO